Perhaps it is not time to switch from whole cell to acellular pertussis vaccineBMJ 2000; 321 doi: https://doi.org/10.1136/bmj.321.7258.451/b (Published 12 August 2000) Cite this as: BMJ 2000;321:451
- David Elliman, consultant in community child health,
- Helen Bedford, senior research fellow
- St George's Hospital, London SW17 0QT
- Department of Epidemiology and Public Health, Institute of Child Health, London WC1N 1EH
EDITOR—Although we agree with Finn and Bell that it is an opportune moment to review the British policy on the use of pertussis vaccines, we cannot agree with their conclusion.1 There is ample evidence that in older children adverse events are less common after the acellular than after the whole cell vaccine, but this difference becomes less significant when the vaccine is given at two, three, and four months as in the United Kingdom.
Miller et …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial